Prognostic Significance of MCM2, Ki-67, and Gelsolin in Non-Small Cell Lung Cancer
Author Information
Author(s): Yang Jun, Ramnath Nithya, Moysich Kirsten B, Asch Harold L, Swede Helen, Alrawi Sadir J, Huberman Joel, Geradts Joseph, Brooks John SJ, Tan Dongfeng
Primary Institution: Roswell Park Cancer Institute
Hypothesis
The study assesses the prognostic significance of MCM2, Ki-67, and gelsolin in non-small cell lung cancer (NSCLC).
Conclusion
Higher tumor proliferation and motility may be important in the prognosis of NSCLC, and using multiple biomarkers may provide better prognostic information than using a single marker.
Supporting Evidence
- Higher levels of gelsolin were significantly associated with an increased risk of death.
- Higher levels of MCM2 were associated with a non-significant increased risk of death.
- Combined higher expression of MCM2 and gelsolin was significantly associated with a higher risk of death.
Takeaway
This study found that higher levels of certain proteins in lung cancer cells can mean a higher risk of death, suggesting that doctors should look at multiple markers to better understand a patient's prognosis.
Methodology
Immunohistochemistry was used to measure the expressions of MCM2, Ki-67, and gelsolin in tumor tissues from 128 patients with resectable NSCLC.
Potential Biases
Potential biases may arise from the retrospective design and the selection criteria for patient inclusion.
Limitations
The study's sample size may limit the generalizability of the findings, and the retrospective nature of the study could introduce bias.
Participant Demographics
The majority of participants were Caucasian (93.8%), with a mean age of 64.2 years, and included more males (54.7%) than females (45.3%).
Statistical Information
P-Value
0.01
Confidence Interval
95% CI = 1.17–3.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website